Acrux announced positive results from its Phase 1 clinical studiesusing two unique contraceptive skin sprays, each containing a progestin and an estrogen.
The first study was a Phase I, pharmacokinetic study, investigating the delivery of a formulation combining Nestorone® and the synthetic estrogen, Ethinyl Estradiol. A single dose of the combination formulation was applied to the forearm of healthy volunteers.
The results showed that the dosing of the contraceptive spray provided effective delivery of both contraceptive agents, with blood concentrations of Nestorone® and Ethinyl Estradiol in the target range expected to provide effective contraception.
The spray was well tolerated, with no serious adverse events recorded.
“This is the first time that the Acrux MDTS® spray technology haseffectively delivered a formulation containing a combination of twodrugs”, commented Acrux CEO Richard Treagus. “We are particularlypleased that our transdermal spray has been successful with EthinylEstradiol, as this is the active pharmaceutical compound in approximately 3 out of every 4 oral contraceptive tablets” he added.
• Ethinyl Estradiol has been effectively delivered through the skin with the Acrux technology for the first time• The global contraceptive market is worth US$6.7 billion, withcombination products comprising >80%• Further clinical trials to commence later this year
Source: Research Australia